BriaCell Therapeutics Corp. ("BriaCell" or the "Company")
(TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology
company specializing in targeted immunotherapy for advanced breast
cancer, today announced that BriaCell’s clinical findings will be
published in the 2019 American Society of Clinical Oncology (ASCO)
Annual Meeting Proceedings, a supplement to the Journal of Clinical
Oncology. ASCO’s Annual Meeting, taking place May 31-June 4, 2019
at the McCormick Place Convention Center in Chicago, IL, represents
the world’s largest gathering of oncology physicians, biotechnology
executives, researchers, and investment analysts to discuss
cutting-edge clinical research and therapeutics in oncology.
Additionally, Dr. Bill Williams, BriaCell’s President
& CEO, will be presenting at the Precision Breast Cancer
Conference, a global Pharma R&D summit, in Boston, MA. The
conference will be held on April 24-25, 2019 at Courtyard by
Marriott Boston Downtown (275 Tremont St, Boston, MA 02116, USA).
“Our clinical data elucidates novel ways to
fight cancer, and solidifies our unique and simple HLA profiling
approach, which provides a precise personalized treatment option
for advanced breast cancer patients. We are pleased with the
inclusion of BriaCell’s clinical data in such high profile
conferences,” said Dr. Williams, BriaCell’s President and CEO. “We
are also thrilled with the prospects of our previously-reported
additive or synergistic anti-tumor activity of Bria-IMT™ in
combination with pembrolizumab [KEYTRUDA®; manufactured by Merck
& Co., Inc. (NYSE: MRK)] offering potential clinical benefit to
advanced breast cancer patients, and look forward to sharing
additional data in the second half of 2019.”
BriaCell is currently conducting a Phase I/IIa
clinical trial of Bria-IMT™, its lead candidate, in a Combination
Study with KEYTRUDA®. The Combination Study is listed in
ClinicalTrials.gov as NCT03328026.
Publication at the 2019 ASCO Annual
Meeting
The abstract summarizes the clinical data on 23
advanced breast cancer patients dosed with Bria-IMT™ in the
completed Phase I/IIa clinical study (NCT03066947). The clinical
data indicated that Bria-IMT™ treatment was safe and
well-tolerated. Tumor regression was seen in several advanced
breast cancer patients who failed a number of previous treatments
prior to the Bria-IMT™ regimen. Importantly, these patients matched
Bria-IMT™ for specific HLA types, providing support for BriaCell’s
hypothesis that Bria-IMT™ works by a unique mechanism of action
which sets it apart from other immunotherapy products. The
findings also support the logic for further development of
Bria-OTS™, BriaCell’s off-the-shelf personalized immunotherapy for
advanced breast cancer, and BriaDX™, BriaCell’s companion
diagnostic identification test. Bria-OTS™ is expected to enter the
clinic in 2019.
Abstract Number for
Publication: e14026Abstract Title: Safety
and efficacy of a phase I/IIa trial (NCT03066947) of a modified
whole tumor cell targeted immunotherapy in patients with advanced
breast cancer.
The majority of abstracts will be released by ASCO on May 15,
2019, at 5:00 PM EDT on abstracts.asco.org.
Presentation at Precision Breast Cancer
Conference
Details of BriaCell’s oral presentation are as
follows:Event: 2019 Precision Breast Cancer
ConferenceDate: Wednesday, April 24,
2019Time: 3:00 PM EDTTitle: Can
Cancer Immunotherapy be both Personalized and
Off-the-Shelf?Location: Courtyard by Marriott
Boston Downtown, 275 Tremont Street, Boston, MA 02116
Dr. Bill Williams will be available for
one-on-one meetings from April 24 to April 25, 2019 in Boston.
To arrange a one-on-one meeting with Dr.
Williams during the event, please contact:
Farrah DeanManager, Corporate DevelopmentEmail:
farrah@BriaCell.comPhone: 1-888-485-6340
An updated presentation will be available for
download at
https://briacell.com/investor-relations/presentations/.
About American Society of Clinical
Oncology (ASCO) Conference
Founded in 1964, ASCO is the world’s leading
professional organization for physicians, oncology professionals,
and research scientists in the field of oncology. ASCO’s Mission
over the years has been to conquering cancer through research,
education, and promotion of the highest quality patient care.
ASCO’s Annual meeting represents the world’s
largest gathering of oncology physicians, biotechnology executives,
researchers, patient advocates, and investment analysts to discuss
cutting-edge clinical research and therapeutics in oncology, and to
gain insights for improving cancer care.
For additional information on the 2019 ASCO’s Annual meeting,
please visit https://www.asco.org/.
About Precision Breast Cancer Conference
Precision Breast Cancer R&D summit provides an opportunity
for senior level biotechnology and pharmaceutical executives,
medical doctors, and scientists to discuss the research and
development of cutting-edge treatments for Breast Cancer. The
conference creates a networking forum for precision medicine
leaders in the breast cancer space with the goal of creating
meaningful collaborations.
For more information on Precision Breast Cancer Conference 2019,
please visit: https://precisionbreastcancer.com/.
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and safe approaches for
the management of cancer.
BriaCell is currently conducting a Phase I/IIa
clinical trial of Bria-IMT™, its lead candidate, in a Combination
Study with pembrolizumab [KEYTRUDA®; manufactured by Merck &
Co., Inc. (NYSE: MRK)]. The Combination Study is listed in
ClinicalTrials.gov as NCT03328026.
BriaCell is developing Bria-OTS™, an
off-the-shelf personalized immunotherapy, for advanced breast
cancer. Bria-OTS™ immunotherapy treatments are personalized to
match the patient without the need for personalized manufacturing.
Bria-OTS™, which is expected to cover over 99 percent of the
patient population, is designed to produce a potent and selective
immune response against the cancer of each patient while
eliminating the time, expense and complex manufacturing logistics
associated with other personalized immunotherapies.
For additional information on BriaCell, please
visit: https://briacell.com/.
Cautionary Note Regarding Forward-Looking
Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation which
involves known and unknown risks relevant to the Company in
particular and to the biotechnology and pharmaceutical industries
in general, uncertainties and other factors that may cause actual
events to differ materially from current expectation. These risks
are more fully described in the Company's public filings available
at www.sedar.com.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please
contact:BriaCell Therapeutics Corp.:Farrah
DeanManager, Corporate DevelopmentEmail: farrah@BriaCell.com Phone:
1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Aug 2024 to Sep 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Sep 2023 to Sep 2024